

# Liver function monitoring scheme with Agomelatine for the treatment of major depressive episodes in adults

Patient name: \_\_\_\_\_

Date of initiation: \_\_\_\_\_

**Agomelatine 25mg**


|  |              |
|--|--------------|
| <input type="checkbox"/> Before Initiation of 25mg | ALT .....U/L |
|  | AST .....U/L |
| <input type="checkbox"/> Week 3                    | ALT .....U/L |
|  | AST .....U/L |
| <input type="checkbox"/> Week 6                    | ALT .....U/L |
|  | AST .....U/L |
| <input type="checkbox"/> Week 12                   | ALT .....U/L |
|  | AST .....U/L |
| <input type="checkbox"/> Week 24                   | ALT .....U/L |
|  | AST .....U/L |

Perform a test at any time if clinically justified.

If dose increased to **50mg**, restart the monitoring scheme.

|   |              |
|---|--------------|
| <input type="checkbox"/> Initiation of 50mg | ALT .....U/L |
|   | AST .....U/L |
| <input type="checkbox"/> Week 3             | ALT .....U/L |
|   | AST .....U/L |
| <input type="checkbox"/> Week 6             | ALT .....U/L |
|   | AST .....U/L |
| <input type="checkbox"/> Week 12            | ALT .....U/L |
|   | AST .....U/L |
| <input type="checkbox"/> Week 24            | ALT .....U/L |
|   | AST .....U/L |

Perform a test at any time if clinically justified.



\* Such as dark urine, light coloured stools, yellow skin/eyes, right upper quadrant abdominal pain, sustained new-onset and unexplained fatigue.